Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 23, 2011 13:19 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma, Inc. Announces it Has Scheduled Its 2010 Annual Stockholders' Meeting to Occur on March 17, 2011 in Remediation of Notice From the NYSE Amex of Non-Compliance With the Requirement to Hold Its Annual Stockholders' Meeting by the End of 2010

PHILADELPHIA, Feb. 23, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB)announced that notice had been received from the Staff of the NYSE Amex (the "Amex") indicating that the...
February 17, 2011 10:00 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Appoints Senior Pharma Executive to Key Manufacturing Position

PHILADELPHIA, Feb. 17, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company"), announced today the appointment of Mr. Ronald Ritz as Senior Director of...
February 17, 2011 08:00 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces US District Court Grants Final Approval of Settlement of Securities Class Actions

PHILADELPHIA, Feb. 17, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") today announced that the United States District Court for the Eastern...
January 04, 2011 10:00 ET | Source: Hemispherx Biopharma, Inc.

FDA Authorizes Alferon LDO Clinical Study for Treatment and Prevention of Influenza

PHILADELPHIA, Jan. 4, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") announced today that the Food and Drug Administration (FDA) has lifted a...
December 28, 2010 16:56 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma, Inc. to Restate 2009 Financial Statements

PHILADELPHIA, Dec. 28, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) announced its intention to restate its financial statements in its Annual Report on Form 10-K for the year...
December 20, 2010 11:00 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Licenses Alferon N Injection(R) to GP Pharm in Latin America

PHILADELPHIA, Dec. 20, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") announced that the Company has entered into an agreement with GP Pharm...
December 14, 2010 10:00 ET | Source: Hemispherx Biopharma, Inc.

FDA Grants Hemispherx Biopharma Extension in Its Pending NDA for Treatment of Chronic Fatigue Syndrome (CFS)

PHILADELPHIA, Dec. 14, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") announced today that the Food and Drug Administration (FDA) granted a 12...
December 09, 2010 08:00 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Extends GP Pharm License to Mexico for Ampligen to Treat for Chronic Fatigue Syndrome in Latin America

PHILADELPHIA, Dec. 9, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") announced that the Company has amended its June 15, 2010 agreement with GP...
November 29, 2010 09:00 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Files With the FDA a Request to Maintain as Active Hemispherx NDA for Ampligen(R) to Treat Chronic Fatigue Syndrome (CFS)

PHILADELPHIA, Nov. 29, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx"), announced that the Company has requested an extension of time in which to...
November 22, 2010 08:00 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Publishes New Data on Ampligen(R)'s Activity in Chronic Fatigue Syndrome (CFS)

PHILADELPHIA, Nov. 22, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company"), announced the publication of a peer-reviewed article providing new data on Ampligen®...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right